Regulation of the ErbB network by the MIG6 feedback loop in physiology, tumor suppression and responses to oncogene-targeted therapeutics

被引:18
作者
Anastasi, Sergio [1 ]
Lamberti, Dante [1 ]
Alema, Stefano [2 ]
Segatto, Oreste [1 ]
机构
[1] Regina Elena Inst Canc Res, Lab Cell Signaling, Via E Chianesi 53, I-00144 Rome, Italy
[2] CNR, Inst Cell Biol & Neurobiol, I-00016 Monterotondo, Italy
关键词
MIG6; ErbB receptors; Feedback inhibition; Tumor suppression; Targeted cancer therapeutics; GROWTH-FACTOR RECEPTOR; INDUCIBLE GENE 6; KRAS MUTANT LUNG; EGF RECEPTOR; NEGATIVE REGULATOR; SIGNALING NETWORKS; BRAF(V600E) INHIBITION; ACQUIRED-RESISTANCE; EPIGENETIC CHANGES; DOWN-REGULATION;
D O I
10.1016/j.semcdb.2015.10.001
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The ErbB signaling network instructs the execution of key cellular programs, such as cell survival, proliferation and motility, through the generation of robust signals of defined strength and duration. In contrast, unabated ErbB signaling disrupts tissue homeostasis and leads to cell transformation. Cells oppose the threat inherent in excessive ErbB activity through several mechanisms of negative feedback regulation. Inducible feedback inhibitors (IFIs) are expressed in the context of transcriptional responses triggered by ErbB signaling, thus being uniquely suited to regulate ErbB activity during the execution of complex cellular programs. This review focuses on MIG6, an IFI that restrains ErbB signaling by mediating ErbB kinase suppression and receptor down-regulation. We will review key issues in MIG6 function, regulation and tumor suppressor activity. Subsequently, the role for MIG6 loss in the pathogenesis of tumors driven by ErbB oncogenes as well as in the generation of cellular addiction to ErbB signaling will be discussed. We will conclude by analyzing feedback inhibition by MIG6 in the context of therapies directed against ErbB and non-ErbB oncogenes. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:115 / 124
页数:10
相关论文
共 102 条
[1]   Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3 [J].
Abel, Ethan V. ;
Basile, Kevin J. ;
Kugel, Curtis H., III ;
Witkiewicz, Agnieszka K. ;
Le, Kaitlyn ;
Amaravadi, Ravi K. ;
Karakousis, Giorgos C. ;
Xu, Xiaowei ;
Xu, Wei ;
Schuchter, Lynn M. ;
Lee, Jason B. ;
Ertel, Adam ;
Fortina, Paolo ;
Aplin, Andrew E. .
JOURNAL OF CLINICAL INVESTIGATION, 2013, 123 (05) :2155-2168
[2]   miR-200 Expression Regulates Epithelial-to-Mesenchymal Transition in Bladder Cancer Cells and Reverses Resistance to Epidermal Growth Factor Receptor Therapy [J].
Adam, Liana ;
Zhong, Meng ;
Choi, Woonyoung ;
Qi, Wei ;
Nicoloso, Milena ;
Arora, Ameeta ;
Calin, George ;
Wang, Hua ;
Siefker-Radtke, Arlene ;
McConkey, David ;
Bar-Eli, Menashe ;
Dinney, Colin .
CLINICAL CANCER RESEARCH, 2009, 15 (16) :5060-5072
[3]   Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy [J].
Amit, Ido ;
Wides, Ron ;
Yarden, Yosef .
MOLECULAR SYSTEMS BIOLOGY, 2007, 3 (1)
[4]   The evolutionarily conserved EBR module of RALT/MIG6 mediates suppression of the EGFR catalytic activity [J].
Anastasi, S. ;
Baietti, M. F. ;
Frosi, Y. ;
Alema, S. ;
Segatto, O. .
ONCOGENE, 2007, 26 (57) :7833-7846
[5]   Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin [J].
Anastasi, S ;
Sala, G ;
Chen, HP ;
Caprini, E ;
Russo, G ;
Iacovelli, S ;
Lucini, F ;
Ingvarsson, S ;
Segatto, O .
ONCOGENE, 2005, 24 (28) :4540-4548
[6]   A pervasive role for MIG6 in restraining cell proliferation [J].
Anastasi, S. ;
Castellani, L. ;
Alema, S. ;
Segatto, O. .
CELL DEATH AND DIFFERENTIATION, 2014, 21 (03) :345-347
[7]   Feedback inhibition by RALT controls signal output by the ErbB network [J].
Anastasi, S ;
Fiorentino, L ;
Fiorini, M ;
Fraioli, R ;
Sala, G ;
Castellani, L ;
Alemà, S ;
Alimandi, M ;
Segatto, O .
ONCOGENE, 2003, 22 (27) :4221-4234
[8]   ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics [J].
Arteaga, Carlos L. ;
Engelman, Jeffrey A. .
CANCER CELL, 2014, 25 (03) :282-303
[9]   RETRACTED: Cytohesins Are Cytoplasmic ErbB Receptor Activators (Retracted article. See vol. 165, pg. 1293, 2016) [J].
Bill, Anke ;
Schmitz, Anton ;
Albertoni, Barbara ;
Song, Jin-Na ;
Heukamp, Lukas C. ;
Walrafen, David ;
Thorwirth, Franziska ;
Verveer, Peter J. ;
Zimmer, Sebastian ;
Meffert, Lisa ;
Schreiber, Arne ;
Chatterjee, Sampurna ;
Thomas, Roman K. ;
Ullrich, Roland T. ;
Lang, Thorsten ;
Famulok, Michael .
CELL, 2010, 143 (02) :201-211
[10]   Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma [J].
Borad, Mitesh J. ;
Champion, Mia D. ;
Egan, Jan B. ;
Liang, Winnie S. ;
Fonseca, Rafael ;
Bryce, Alan H. ;
McCullough, Ann E. ;
Barrett, Michael T. ;
Hunt, Katherine ;
Patel, Maitray D. ;
Young, Scott W. ;
Collins, Joseph M. ;
Silva, Alvin C. ;
Condjella, Rachel M. ;
Block, Matthew ;
McWilliams, Robert R. ;
Lazaridis, Konstantinos N. ;
Klee, Eric W. ;
Bible, Keith C. ;
Harris, Pamela ;
Oliver, Gavin R. ;
Bhavsar, Jaysheel D. ;
Nair, Asha A. ;
Middha, Sumit ;
Asmann, Yan ;
Kocher, Jean-Pierre ;
Schahl, Kimberly ;
Kipp, Benjamin R. ;
Fritcher, Emily G. Barr ;
Baker, Angela ;
Aldrich, Jessica ;
Kurdoglu, Ahmet ;
Izatt, Tyler ;
Christoforides, Alexis ;
Cherni, Irene ;
Nasser, Sara ;
Reiman, Rebecca ;
Phillips, Lori ;
McDonald, Jackie ;
Adkins, Jonathan ;
Mastrian, Stephen D. ;
Placek, Pamela ;
Watanabe, Aprill T. ;
LoBello, Janine ;
Han, Haiyong ;
Von Hoff, Daniel ;
Craig, David W. ;
Stewart, A. Keith ;
Carpten, John D. .
PLOS GENETICS, 2014, 10 (02)